Fundamental & Clinical Pharmacology最新文献_第8页

Role of biomarkers and molecular signaling pathways in acute lung injury 生物标志物和分子信号通路在急性肺损伤中的作用。

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-26 DOI: 10.1111/fcp.12987

Pakter Niri, Achintya Saha, Subramanyam Polopalli, Mohit Kumar, Sanghita Das, Pronobesh Chattopadhyay

Background

Acute lung injury (ALI) is caused by bacterial, fungal, and viral infections. When pathogens invade the lungs, the immune system responds by producing cytokines, chemokines, and interferons to promote the infiltration of phagocytic cells, which are essential for pathogen clearance. Their excess production causes an overactive immune response and a pathological hyper-inflammatory state, which leads to ALI. Until now, there is no particular pharmaceutical treatment available for ALI despite known inflammatory mediators like neutrophil extracellular traps (NETs) and reactive oxygen species (ROS).

Objectives

Therefore, the primary objective of this review is to provide the clear overview on the mechanisms controlling NETs, ROS formation, and other relevant processes during the pathogenesis of ALI. In addition, we have discussed the significance of epithelial and endothelial damage indicators and several molecular signaling pathways associated with ALI.

Methods

The literature review was done from Web of Science, Scopus, PubMed, and Google Scholar for ALI, NETs, ROS, inflammation, biomarkers, Toll- and nucleotide-binding oligomerization domain (NOD)-like receptors, alveolar damage, pro-inflammatory cytokines, and epithelial/endothelial damage alone or in combination.

Results

This review summarized the main clinical signs of ALI, including the regulation and distinct function of epithelial and endothelial biomarkers, NETs, ROS, and pattern recognition receptors (PRRs).

Conclusion

However, no particular drugs including vaccine for ALI has been established. Furthermore, there is a lack of validated diagnostic tools and a poor predictive rationality of current therapeutic biomarkers. Hence, extensive and precise research is required to speed up the process of drug testing and development by the application of artificial intelligence technologies, structure-based drug design, in-silico approaches, and drug repurposing.

背景：急性肺损伤（ALI）是由细菌、真菌和病毒感染引起的。当病原体侵入肺部时，免疫系统会产生细胞因子、趋化因子和干扰素，以促进吞噬细胞的浸润。细胞因子、趋化因子和干扰素的过量产生会导致过度活跃的免疫反应和病理性高炎症状态，从而引发 ALI。迄今为止，尽管已知有中性粒细胞胞外捕获物（NETs）和活性氧（ROS）等炎症介质，但仍没有治疗 ALI 的特效药物：因此，本综述的主要目的是提供关于控制中性粒细胞胞外捕获物（NETs）、活性氧（ROS）形成的机制以及 ALI 发病过程中其他相关过程的清晰概述。此外，我们还讨论了上皮和内皮损伤指标的重要性以及与 ALI 相关的几种分子信号通路：方法：我们从 Web of Science、Scopus、PubMed 和 Google Scholar 上查阅了有关 ALI、NETs、ROS、炎症、生物标志物、Toll 和核苷酸结合寡聚域（NOD）样受体、肺泡损伤、促炎细胞因子以及上皮/内皮损伤的单独或组合的文献：本综述总结了 ALI 的主要临床表现，包括上皮和内皮生物标志物、NETs、ROS 和模式识别受体（PRRs）的调节和不同功能：然而，目前还没有针对 ALI 的特定药物（包括疫苗）。此外，目前还缺乏有效的诊断工具，现有治疗生物标志物的预测合理性也很差。因此，需要开展广泛而精确的研究，通过应用人工智能技术、基于结构的药物设计、硅内方法和药物再利用，加快药物测试和开发进程。

{"title":"Role of biomarkers and molecular signaling pathways in acute lung injury","authors":"Pakter Niri, Achintya Saha, Subramanyam Polopalli, Mohit Kumar, Sanghita Das, Pronobesh Chattopadhyay","doi":"10.1111/fcp.12987","DOIUrl":"10.1111/fcp.12987","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute lung injury (ALI) is caused by bacterial, fungal, and viral infections. When pathogens invade the lungs, the immune system responds by producing cytokines, chemokines, and interferons to promote the infiltration of phagocytic cells, which are essential for pathogen clearance. Their excess production causes an overactive immune response and a pathological hyper-inflammatory state, which leads to ALI. Until now, there is no particular pharmaceutical treatment available for ALI despite known inflammatory mediators like neutrophil extracellular traps (NETs) and reactive oxygen species (ROS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Therefore, the primary objective of this review is to provide the clear overview on the mechanisms controlling NETs, ROS formation, and other relevant processes during the pathogenesis of ALI. In addition, we have discussed the significance of epithelial and endothelial damage indicators and several molecular signaling pathways associated with ALI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The literature review was done from Web of Science, Scopus, PubMed, and Google Scholar for ALI, NETs, ROS, inflammation, biomarkers, Toll- and nucleotide-binding oligomerization domain (NOD)-like receptors, alveolar damage, pro-inflammatory cytokines, and epithelial/endothelial damage alone or in combination.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This review summarized the main clinical signs of ALI, including the regulation and distinct function of epithelial and endothelial biomarkers, NETs, ROS, and pattern recognition receptors (PRRs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>However, no particular drugs including vaccine for ALI has been established. Furthermore, there is a lack of validated diagnostic tools and a poor predictive rationality of current therapeutic biomarkers. Hence, extensive and precise research is required to speed up the process of drug testing and development by the application of artificial intelligence technologies, structure-based drug design, <i>in-silico</i> approaches, and drug repurposing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 4","pages":"640-657"},"PeriodicalIF":2.1,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study 与 PARPi 相关的动脉高血压：41 项安慰剂随机对照试验与世界卫生组织药物警戒研究的荟萃分析。

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-25 DOI: 10.1111/fcp.12984

Clémence Blaize, Ellina Surtouque, Jonaz Font, Charles Dolladille, Sophie Postel-Vinay, Angélique Da Silva, Joachim Alexandre, Pierre-Marie Morice

Background

Arterial hypertension has been recently reported from randomized controlled trials (RCTs) assessing poly (ADP-ribose) polymerase inhibitor (PARPi).

Objective

In a context of increasing use of PARPi, it is crucial to properly assess risk and incidence of this adverse event for clinical practice.

Methods

We performed a systematic review and meta-analysis in MEDLINE, Cochrane CENTRAL and ClinicalTrials.gov up to January 4, 2023 with an ongoing surveillance up to June 7, 2023. RCTs comparing PARPi to placebo in adult patients with solid tumors were included if hypertension was reported. The primary outcome was the summary risk ratio (RR, with 95% CIs) of any hypertension of PARPi class in placebo RCTs. Secondary outcomes were the summary risk and incidence of hypertension of each individual PARPi. To provide clinical features of PARPi-associated hypertension, we independently queried the WHO's pharmacovigilance database, up to September 1, 2022.

Results

In total, 41 placebo RCTs (n = 15 264 adult patients) were included. PARPi class was not associated with an increased risk of hypertension compared with placebo. In individual analyses, the risk of hypertension was lower with olaparib than placebo (RR 0.77 [95% CI: 0.68–0.86], P < 0.01; I² = 19%, χ² P = 0.26). Niraparib monotherapy increased the risk of any (RR 2.84 [95% CI: 1.76–4.57], P < 0.01; I² = 66%, χ² P = 0.01) hypertension with a summary incidence of 19.87% (95% CI: 15.23–25.50). In real-life setting, niraparib-associated hypertension occurs within 20 days and was serious in 66%. Co-prescription of at least one antihypertensive or therapy-induced hypertension was reported in 20.5% or 14.4% of cases, respectively.

Conclusions

In a context of extensive assessment of niraparib in combination, these data reinforce the need of a close monitoring of this adverse event to preserve its clinical benefit on patients' survival.

背景：最近，评估聚（ADP-核糖）聚合酶抑制剂（PARPi）的随机对照试验（RCT）报告了动脉高血压：在越来越多地使用 PARPi 的情况下，正确评估这一不良事件的风险和发生率对于临床实践至关重要：截至 2023 年 1 月 4 日，我们在 MEDLINE、Cochrane CENTRAL 和 ClinicalTrials.gov 上进行了系统回顾和荟萃分析，并持续监测至 2023 年 6 月 7 日。如果报告了高血压，则纳入在实体瘤成年患者中比较 PARPi 和安慰剂的 RCT。主要结果是安慰剂 RCT 中 PARPi 类任何高血压的总风险比 (RR，含 95% CIs)。次要结果是每种 PARPi 的高血压总风险和发病率。为了提供 PARPi 相关高血压的临床特征，我们独立查询了世界卫生组织的药物警戒数据库（截至 2022 年 9 月 1 日）：结果：共纳入 41 项安慰剂 RCT（n = 15 264 名成年患者）。与安慰剂相比，PARPi 类药物与高血压风险增加无关。在单项分析中，奥拉帕利的高血压风险低于安慰剂（RR 0.77 [95% CI：0.68-0.86]，P 2 = 19%，χ2 P = 0.26）。尼拉帕利单药治疗会增加任何高血压的风险（RR 2.84 [95% CI：1.76-4.57]，P 2 = 66%，χ2 P = 0.01），总发生率为 19.87%（95% CI：15.23-25.50）。在现实生活中，尼拉帕利相关高血压发生在 20 天内，66% 的患者病情严重。据报道，20.5%或14.4%的病例同时服用了至少一种降压药或治疗引起的高血压：结论：在对尼拉帕利联合用药进行广泛评估的背景下，这些数据强化了密切监测这一不良事件的必要性，以保持其对患者生存的临床益处。

{"title":"Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study","authors":"Clémence Blaize, Ellina Surtouque, Jonaz Font, Charles Dolladille, Sophie Postel-Vinay, Angélique Da Silva, Joachim Alexandre, Pierre-Marie Morice","doi":"10.1111/fcp.12984","DOIUrl":"10.1111/fcp.12984","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Arterial hypertension has been recently reported from randomized controlled trials (RCTs) assessing poly (ADP-ribose) polymerase inhibitor (PARPi).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>In a context of increasing use of PARPi, it is crucial to properly assess risk and incidence of this adverse event for clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a systematic review and meta-analysis in MEDLINE, Cochrane CENTRAL and ClinicalTrials.gov up to January 4, 2023 with an ongoing surveillance up to June 7, 2023. RCTs comparing PARPi to placebo in adult patients with solid tumors were included if hypertension was reported. The primary outcome was the summary risk ratio (RR, with 95% CIs) of any hypertension of PARPi class in placebo RCTs. Secondary outcomes were the summary risk and incidence of hypertension of each individual PARPi. To provide clinical features of PARPi-associated hypertension, we independently queried the WHO's pharmacovigilance database, up to September 1, 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 41 placebo RCTs (<i>n</i> = 15 264 adult patients) were included. PARPi class was not associated with an increased risk of hypertension compared with placebo. In individual analyses, the risk of hypertension was lower with olaparib than placebo (RR 0.77 [95% CI: 0.68–0.86], <i>P</i> < 0.01; <i>I</i><sup>2</sup> = 19%, χ<sup>2</sup> <i>P</i> = 0.26). Niraparib monotherapy increased the risk of any (RR 2.84 [95% CI: 1.76–4.57], <i>P</i> < 0.01; <i>I</i><sup>2</sup> = 66%, χ<sup>2</sup> <i>P</i> = 0.01) hypertension with a summary incidence of 19.87% (95% CI: 15.23–25.50). In real-life setting, niraparib-associated hypertension occurs within 20 days and was serious in 66%. Co-prescription of at least one antihypertensive or therapy-induced hypertension was reported in 20.5% or 14.4% of cases, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In a context of extensive assessment of niraparib in combination, these data reinforce the need of a close monitoring of this adverse event to preserve its clinical benefit on patients' survival.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 4","pages":"610-629"},"PeriodicalIF":2.1,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sodium hypochlorite accident diagnosis and management: Analysis from the literature and the French pharmacovigilance database 次氯酸钠事故的诊断和处理：文献和法国药物警戒数据库分析。

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-24 DOI: 10.1111/fcp.12985

Zahoua Kartit, Céline Delacroix, Céline Clement, Mathilde Beurrier, Claudie Mouton-Faivre, Nadine Petitpain

Purpose

Sodium hypochlorite (NaOCl) is considered as the reference irrigation solution in endodontics. However, NaOCl-related accidents may occur, and non-dentist health professionals might under-recognize this rare adverse effect although it is potentially severe, with possible medical and aesthetic sequelae. We performed a literature review to provide to non-dentist healthcare professionals a large picture of symptoms, management and potential consequences of NaOCl accidents.

Methods

We queried PubMed and the French Pharmacovigilance database and retrieved 76 cases for analysis (70 from 57 published articles, and six from the database).

Results

The analysis showed that patients were mostly women (79%), aged around of 42 years, undergoing upper jawbone (74%) endodontic procedure. NaOCl concentration ranged from 1% to 10%, with 0.5 to 30 mL injected. Most cases (86%) corresponded to an accidental extrusion beyond the root apex to the periapical tissues, followed by tissular injection by error (8%) and extrusion into the maxillary sinus (3%). Local symptoms always occurred within 24 h, mostly pain (99%), edema (89%) and/or ecchymosis (61%). Complications were mainly neurological (29%), necrotic (22%) and cutaneous (9%). Most of patients (76%) fully recovered after medical management but 18 (24%) required surgical management.

Conclusion

Any healthcare professional should be aware of the classical symptomatic triad of NaOCl accident with sudden pain, haemorrhage/ecchymosis and swelling, to start or recommend adequate management. Patients should be reassured, but a close follow-up is necessary to avoid delayed complication.

目的：次氯酸钠（NaOCl）被认为是牙髓病学的参考灌洗溶液。然而，与次氯酸钠相关的事故可能会发生，非牙科医生保健专业人员可能对这种罕见的不良反应认识不足，尽管这种不良反应可能很严重，并可能带来医疗和美学后遗症。我们进行了一次文献综述，旨在为非牙科医生的医疗保健专业人员提供有关 NaOCl 事故的症状、处理方法和潜在后果的全面信息：我们查询了 PubMed 和法国药物警戒数据库，并检索了 76 个病例进行分析（其中 70 例来自 57 篇发表的文章，6 例来自数据库）：分析结果显示，患者多为女性（79%），年龄在 42 岁左右，正在接受上颌骨牙髓治疗（74%）。NaOCl 浓度从 1%到 10%不等，注射量从 0.5 毫升到 30 毫升不等。大多数病例（86%）是由于意外挤出根尖至根尖周围组织，其次是组织注射错误（8%）和挤入上颌窦（3%）。局部症状总是在 24 小时内出现，主要是疼痛（99%）、水肿（89%）和/或瘀斑（61%）。并发症主要是神经系统（29%）、坏死（22%）和皮肤（9%）。大多数患者（76%）在接受内科治疗后完全康复，但有18名患者（24%）需要接受外科治疗：任何医护人员都应了解 NaOCl 事故的典型症状三联征，即突然疼痛、出血/瘀斑和肿胀，以便开始或建议适当的治疗。患者应得到安抚，但有必要进行密切随访，以避免延误并发症的发生。

{"title":"Sodium hypochlorite accident diagnosis and management: Analysis from the literature and the French pharmacovigilance database","authors":"Zahoua Kartit, Céline Delacroix, Céline Clement, Mathilde Beurrier, Claudie Mouton-Faivre, Nadine Petitpain","doi":"10.1111/fcp.12985","DOIUrl":"10.1111/fcp.12985","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Sodium hypochlorite (NaOCl) is considered as the reference irrigation solution in endodontics. However, NaOCl-related accidents may occur, and non-dentist health professionals might under-recognize this rare adverse effect although it is potentially severe, with possible medical and aesthetic sequelae. We performed a literature review to provide to non-dentist healthcare professionals a large picture of symptoms, management and potential consequences of NaOCl accidents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We queried PubMed and the French Pharmacovigilance database and retrieved 76 cases for analysis (70 from 57 published articles, and six from the database).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis showed that patients were mostly women (79%), aged around of 42 years, undergoing upper jawbone (74%) endodontic procedure. NaOCl concentration ranged from 1% to 10%, with 0.5 to 30 mL injected. Most cases (86%) corresponded to an accidental extrusion beyond the root apex to the periapical tissues, followed by tissular injection by error (8%) and extrusion into the maxillary sinus (3%). Local symptoms always occurred within 24 h, mostly pain (99%), edema (89%) and/or ecchymosis (61%). Complications were mainly neurological (29%), necrotic (22%) and cutaneous (9%). Most of patients (76%) fully recovered after medical management but 18 (24%) required surgical management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Any healthcare professional should be aware of the classical symptomatic triad of NaOCl accident with sudden pain, haemorrhage/ecchymosis and swelling, to start or recommend adequate management. Patients should be reassured, but a close follow-up is necessary to avoid delayed complication.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 4","pages":"630-639"},"PeriodicalIF":2.1,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Repurposing of atorvastatin and metformin denotes their individual and combined antiproliferative effects in non-small cell lung cancer 阿托伐他汀和二甲双胍的再利用表明了它们在非小细胞肺癌中的单独和联合抗增殖作用。

IF 2.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-23 DOI: 10.1111/fcp.12981

Elsayed I. Salim, Safaa Elsebakhy, Mohamed Hessien

Background

Due to the limited success in the treatment of lung adenocarcinomas, new treatment protocols are urgently needed to increase the curability rate and the survival of lung cancer patients.

Objectives

Although statins, like atorvastatin (Ator), and metformin (Met) are widely accepted as hypolipidemic and hypoglycemic drugs, respectively, there are many predictions about their enhancing antitumor effect when they are combined with traditional chemotherapeutics.

Methods

The individual and combined antiproliferative potential of Ator and Met was tested by MTT-assay in non-small cell lung cancer (NSCLC) A549 cell line, compared to the corresponding effect of Gemcitabine (Gem) with implication on the mechanisms of action.

Results

Initially, both drugs demonstrated concentration-dependent cytotoxicity in A549 cells. Also, their combination index (CI) indicated their synergistic effect at equi-IC50 concentration (CI = 0.00984). Moreover, Ator and/or Met-treated cells revealed disrupted patterns of SOD, CAT, GSH, MDA, and TAC, developed apoptosis, and larger fractions of the cell population were arrested in G0/G1 phase, particularly in cells dually-treated both Ator and Met. These observations were accompanied by downregulation in the expression of iNOS, HO-1, and the angiogenic marker VEGF, meanwhile, an altered expression of MAPK and AMPK was observed.

Conclusion

Conclusively, these data suggest that repurposing of Ator and Met demonstrates their individual and combined antiproliferative effect in non-small cell lung cancer and they may adopt a similar mechanism of action.

背景：由于肺腺癌的治疗效果有限，迫切需要新的治疗方案来提高肺腺癌患者的治愈率和生存率：由于肺腺癌的治疗效果有限，因此迫切需要新的治疗方案来提高肺腺癌患者的治愈率和生存率：尽管他汀类药物（如阿托伐他汀（Atorvastatin，Ator））和二甲双胍（Met）分别作为降脂药和降糖药被广泛接受，但有很多人预测它们与传统化疗药联合使用会增强抗肿瘤效果：方法：在非小细胞肺癌（NSCLC）A549 细胞系中用 MTT 分析法检测了 Ator 和 Met 的单独和联合抗增殖潜力，并与吉西他滨（Gem）的相应作用进行了比较，同时对其作用机制进行了探讨：结果：最初，这两种药物在A549细胞中都表现出浓度依赖性细胞毒性。此外，它们的联合指数（CI）表明，在等效 IC50 浓度下，它们具有协同效应（CI = 0.00984）。此外，Ator 和/或 Met 处理过的细胞显示出 SOD、CAT、GSH、MDA 和 TAC 的紊乱模式，出现细胞凋亡，更多的细胞群停滞在 G0/G1 期，尤其是在同时使用 Ator 和 Met 的细胞中。这些观察结果伴随着 iNOS、HO-1 和血管生成标志物 VEGF 表达的下调，同时还观察到 MAPK 和 AMPK 表达的改变：总之，这些数据表明，Ator 和 Met 的再利用显示了它们在非小细胞肺癌中的单独和联合抗增殖作用，而且它们可能采用类似的作用机制。

{"title":"Repurposing of atorvastatin and metformin denotes their individual and combined antiproliferative effects in non-small cell lung cancer","authors":"Elsayed I. Salim, Safaa Elsebakhy, Mohamed Hessien","doi":"10.1111/fcp.12981","DOIUrl":"10.1111/fcp.12981","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Due to the limited success in the treatment of lung adenocarcinomas, new treatment protocols are urgently needed to increase the curability rate and the survival of lung cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Although statins, like atorvastatin (Ator), and metformin (Met) are widely accepted as hypolipidemic and hypoglycemic drugs, respectively, there are many predictions about their enhancing antitumor effect when they are combined with traditional chemotherapeutics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The individual and combined antiproliferative potential of Ator and Met was tested by MTT-assay in non-small cell lung cancer (NSCLC) A549 cell line, compared to the corresponding effect of Gemcitabine (Gem) with implication on the mechanisms of action.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Initially, both drugs demonstrated concentration-dependent cytotoxicity in A549 cells. Also, their combination index (CI) indicated their synergistic effect at equi-IC50 concentration (CI = 0.00984). Moreover, Ator and/or Met-treated cells revealed disrupted patterns of SOD, CAT, GSH, MDA, and TAC, developed apoptosis, and larger fractions of the cell population were arrested in G0/G1 phase, particularly in cells dually-treated both Ator and Met. These observations were accompanied by downregulation in the expression of <i>iNOS</i>, <i>HO-1</i>, and the angiogenic marker <i>VEGF</i>, meanwhile, an altered expression of <i>MAPK</i> and <i>AMPK</i> was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Conclusively, these data suggest that repurposing of Ator and Met demonstrates their individual and combined antiproliferative effect in non-small cell lung cancer and they may adopt a similar mechanism of action.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 3","pages":"550-560"},"PeriodicalIF":2.9,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Probing polypharmacy, ageing and sex effects on physical function using different tests 使用不同的测试探究多种药物、老龄化和性别对身体功能的影响。

IF 2.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-21 DOI: 10.1111/fcp.12978

Gizem Gemikonakli, John Mach, Trang Tran, Harry Wu, Sarah N. Hilmer

Background

Ageing, sex and polypharmacy affect physical function.

Objectives

This mouse study investigates how ageing, sex and polypharmacy interact and affect grip strength, balance beam and wire hang, correlating and comparing the different test results between and within subgroups.

Methods

Young (2.5 months) and old (21.5 months) C57BL/6 J male and female mice (n = 10–6/group) were assessed for physical function at baseline on grip strength, balance beam and wire hang with three trials of 60 s (WH60s) and one trial of 300 s (WH300s). Mice were randomised to control or diet containing a high Drug Burden Index (DBI, total anticholinergic and sedative drug exposure) polypharmacy regimen (metoprolol, simvastatin, citalopram, oxycodone and oxybutynin at therapeutic oral doses). Following 6–8 weeks of treatment, mice were reassessed.

Results

High DBI polypharmacy and control mice both showed age group differences on all tests (p < 0.05). Only control mice showed sex differences, with females outperforming males on the WH60s and balance beam for old mice, WH300s for young mice (p < 0.05). Polypharmacy reduced grip strength in all subgroups (p < 0.05) and only in old females reduced wire hang time and cumulative behaviour and balance beam time and %walked (p < 0.05). Physical function assessments were all correlated with each other, with differences between subgroups (p < 0.05), and mice within subgroups showed interindividual variability in performance.

Conclusion

Age, sex and polypharmacy have variable effects on different tests, and behavioural measures are useful adjuvants to assessing performance. There was considerable within-group variability in change in measures over time. These findings can inform design and sample size of future studies.

背景老龄化、性别和多种药物影响身体功能：这项小鼠研究探讨了老龄化、性别和多种药物如何相互作用并影响握力、平衡木和吊线，并对亚组之间和亚组内的不同测试结果进行了关联和比较：方法：年轻（2.5 个月）和年老（21.5 个月）的 C57BL/6 J 雄性和雌性小鼠（n = 10-6/组）在基线时接受握力、平衡木和吊线的身体功能评估，其中包括三次 60 秒（WH60s）和一次 300 秒（WH300s）的测试。小鼠被随机分配到对照组或含有高药物负担指数（DBI，抗胆碱能和镇静药物总暴露量）的多药方案（治疗口服剂量的美托洛尔、辛伐他汀、西酞普兰、羟考酮和羟丁宁）的饮食中。治疗 6-8 周后，对小鼠进行重新评估：结果：高 DBI 多药小鼠和对照组小鼠在所有测试中均显示出年龄组差异（p 结论：高 DBI 多药小鼠和对照组小鼠在所有测试中均显示出年龄组差异：年龄、性别和多药性对不同测试的影响各不相同，行为测量是评估成绩的有用辅助手段。随着时间的推移，行为指标的变化在组内存在相当大的差异。这些发现可为今后研究的设计和样本大小提供参考。

{"title":"Probing polypharmacy, ageing and sex effects on physical function using different tests","authors":"Gizem Gemikonakli, John Mach, Trang Tran, Harry Wu, Sarah N. Hilmer","doi":"10.1111/fcp.12978","DOIUrl":"10.1111/fcp.12978","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ageing, sex and polypharmacy affect physical function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This mouse study investigates how ageing, sex and polypharmacy interact and affect grip strength, balance beam and wire hang, correlating and comparing the different test results between and within subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Young (2.5 months) and old (21.5 months) C57BL/6 J male and female mice (<i>n =</i> 10–6/group) were assessed for physical function at baseline on grip strength, balance beam and wire hang with three trials of 60 s (WH60s) and one trial of 300 s (WH300s). Mice were randomised to control or diet containing a high Drug Burden Index (DBI, total anticholinergic and sedative drug exposure) polypharmacy regimen (metoprolol, simvastatin, citalopram, oxycodone and oxybutynin at therapeutic oral doses). Following 6–8 weeks of treatment, mice were reassessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>High DBI polypharmacy and control mice both showed age group differences on all tests (<i>p <</i> 0.05). Only control mice showed sex differences, with females outperforming males on the WH60s and balance beam for old mice, WH300s for young mice (<i>p <</i> 0.05). Polypharmacy reduced grip strength in all subgroups (<i>p <</i> 0.05) and only in old females reduced wire hang time and cumulative behaviour and balance beam time and %walked (<i>p <</i> 0.05). Physical function assessments were all correlated with each other, with differences between subgroups (<i>p <</i> 0.05), and mice within subgroups showed interindividual variability in performance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Age, sex and polypharmacy have variable effects on different tests, and behavioural measures are useful adjuvants to assessing performance. There was considerable within-group variability in change in measures over time. These findings can inform design and sample size of future studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 3","pages":"561-574"},"PeriodicalIF":2.9,"publicationDate":"2024-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/fcp.12978","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on monkeypox virus infection: Focusing current treatment and prevention approaches 猴痘病毒感染的最新情况：聚焦当前的治疗和预防方法。

IF 2.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-16 DOI: 10.1111/fcp.12980

Rishika Dhapola, Sneha Kumari, Prajjwal Sharma, Pramod KumarKushawaha, Dibbanti HariKrishnaReddy

Background

While the world is still facing the global pandemic COVID-19, another zoonosis monkeypox (Mpox) has emerged posing a great threat to society. Insight into the pathogenesis, symptoms, and management strategies will aid in the development of potent therapeutics for the treatment of monkeypox virus infection.

Objectives

To get insight into the current treatment and prevention strategies will aid in effectively coping with the disease.

Methods

For obtaining information regarding the ongoing treatment and prevention strategies and the drugs under pipeline, we referred to Google Scholar, Pub Med, Pub Chem, and WHO official site.

Results

There are a few drugs that came out to be effective for the treatment of Mpox. Tecovirimat acts by inhibiting viral replication and viral wrapping. Another drug is cidofovir, which hinders the activity of viral DNA polymerase but has the drawback of nephrotoxicity. To overcome this, a conjugate of cidofovir is being used—known as brincidofovir—which has a similar mechanism as cidofovir but lesser toxicity. Ribavirin acts via inhibiting inosine monophosphate dehydrogenase (IMPDPH) thus disrupting viral translation. It also interferes with helicase activity. Tiazofurin, Adenosine N1 oxide, and HPMPA have shown efficacy in in-vitro studies by inhibiting IMPDH, DNA polymerase, and viral mRNA translation respectively. In-silico studies have proven the effect of nilotinib, simeprevir, and dihydroergotamine for Mpox treatment. They have shown binding affinity for proteins required for the growth and release of MPXV. Vaccines have also been employed for the prevention of Mpox, which includes JYNNEOS, ACAM2000, and VIGIV.

Conclusion

This review highlights the pathogenesis of the virus, disease manifestations, drugs, and vaccines that are being used and those under pipeline for the treatment and prevention of Mpox.

背景：当全球仍在面对COVID-19大流行病时，另一种人畜共患病猴痘（Mpox）也已出现，对社会构成了巨大威胁。对猴痘的发病机理、症状和治疗策略的深入了解将有助于开发治疗猴痘病毒感染的有效疗法：深入了解当前的治疗和预防策略将有助于有效应对该疾病：方法：为了获取有关当前治疗和预防策略以及正在研发的药物的信息，我们参考了谷歌学术、Pub Med、Pub Chem和世界卫生组织官方网站：结果：有几种药物对治疗麻风腮有效。Tecovirimat 通过抑制病毒复制和病毒包裹发挥作用。另一种药物是西多福韦，它能阻碍病毒 DNA 聚合酶的活性，但有肾毒性的缺点。为了克服这一缺点，目前正在使用一种西多福韦的共轭物，即布林昔多福韦，其作用机制与西多福韦相似，但毒性较小。利巴韦林通过抑制单磷酸肌苷脱氢酶（IMPDPH）发挥作用，从而破坏病毒的翻译。它还能干扰螺旋酶的活性。噻唑呋林、氧化腺苷 N1 和 HPMPA 分别通过抑制 IMPDH、DNA 聚合酶和病毒 mRNA 翻译，在体外研究中显示出疗效。室内研究证明了尼罗替尼、西美普韦和双氢麦角胺治疗 Mpox 的效果。它们显示出与 MPXV 生长和释放所需的蛋白质的结合亲和力。疫苗也被用于预防 Mpox，包括 JYNNEOS、ACAM2000 和 VIGIV：本综述重点介绍了病毒的致病机理、疾病表现、药物以及用于治疗和预防麻腮风的疫苗。

{"title":"Update on monkeypox virus infection: Focusing current treatment and prevention approaches","authors":"Rishika Dhapola, Sneha Kumari, Prajjwal Sharma, Pramod KumarKushawaha, Dibbanti HariKrishnaReddy","doi":"10.1111/fcp.12980","DOIUrl":"10.1111/fcp.12980","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While the world is still facing the global pandemic COVID-19, another zoonosis monkeypox (Mpox) has emerged posing a great threat to society. Insight into the pathogenesis, symptoms, and management strategies will aid in the development of potent therapeutics for the treatment of monkeypox virus infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To get insight into the current treatment and prevention strategies will aid in effectively coping with the disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>For obtaining information regarding the ongoing treatment and prevention strategies and the drugs under pipeline, we referred to Google Scholar, Pub Med, Pub Chem, and WHO official site.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There are a few drugs that came out to be effective for the treatment of Mpox. Tecovirimat acts by inhibiting viral replication and viral wrapping. Another drug is cidofovir, which hinders the activity of viral DNA polymerase but has the drawback of nephrotoxicity. To overcome this, a conjugate of cidofovir is being used—known as brincidofovir—which has a similar mechanism as cidofovir but lesser toxicity. Ribavirin acts via inhibiting inosine monophosphate dehydrogenase (IMPDPH) thus disrupting viral translation. It also interferes with helicase activity. Tiazofurin, Adenosine N1 oxide, and HPMPA have shown efficacy in in-vitro studies by inhibiting IMPDH, DNA polymerase, and viral mRNA translation respectively. <i>In-silico</i> studies have proven the effect of nilotinib, simeprevir, and dihydroergotamine for Mpox treatment. They have shown binding affinity for proteins required for the growth and release of MPXV. Vaccines have also been employed for the prevention of Mpox, which includes JYNNEOS, ACAM2000, and VIGIV.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This review highlights the pathogenesis of the virus, disease manifestations, drugs, and vaccines that are being used and those under pipeline for the treatment and prevention of Mpox.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 3","pages":"465-478"},"PeriodicalIF":2.9,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell–cell communication in stem cells and cancer: Alone but in touch 干细胞和癌症中的细胞间通讯：孤军奋战却又亲密无间

IF 2.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-16 DOI: 10.1111/fcp.12982

Mehran Radak, Hossein Fallahi

Background

Cellular communication and signaling pathways are fundamental regulators of stem cell and cancer cell behaviors. This review explores the intricate interplay of these pathways in governing cellular behaviors, focusing on their implications for diseases, particularly cancer.

Objectives

This comprehensive review aims to elucidate the significance of cellular signaling pathways in regulating the behavior of stem cells and cancer cells. It delves into the alterations in these pathways, their impact on cell fate, and their implications for developing diseases, notably cancer. The objective is to underscore the importance of understanding these signaling pathways for developing targeted therapeutic strategies.

Methods

The review critically analyzes existing literature and research findings concerning the roles of signaling pathways in stem cell behavior regulation, emphasizing their parallels and disparities in cancer cells. It synthesizes information on both direct and indirect modes of cell communication to delineate the complexity of signaling networks.

Results

Direct and indirect modes of cell communication intricately regulate the complex signaling pathways governing stem cell behaviors, influencing differentiation potential and tissue regeneration. Alterations in these pathways significantly impact stem cell fate, contributing to disease pathogenesis, including cancer. Understanding these signaling cascades offers insights into developing targeted therapies, particularly cancer treatment.

Conclusion

Understanding the regulation of signaling pathways in stem cells and the specialized subset of cancer stem cells holds promise for innovative therapeutic approaches. By targeting aberrant signaling pathways, tailored interventions may improve treatment outcomes. This review underscores the critical role of signaling pathways in cellular behaviors, offering a pathway toward developing novel, more effective therapies for diverse diseases and disorders.

细胞通讯和信号通路是干细胞和癌细胞行为的基本调节器。这篇综述探讨了这些途径在调控细胞行为方面错综复杂的相互作用，重点关注它们对疾病（尤其是癌症）的影响。

{"title":"Cell–cell communication in stem cells and cancer: Alone but in touch","authors":"Mehran Radak, Hossein Fallahi","doi":"10.1111/fcp.12982","DOIUrl":"10.1111/fcp.12982","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cellular communication and signaling pathways are fundamental regulators of stem cell and cancer cell behaviors. This review explores the intricate interplay of these pathways in governing cellular behaviors, focusing on their implications for diseases, particularly cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This comprehensive review aims to elucidate the significance of cellular signaling pathways in regulating the behavior of stem cells and cancer cells. It delves into the alterations in these pathways, their impact on cell fate, and their implications for developing diseases, notably cancer. The objective is to underscore the importance of understanding these signaling pathways for developing targeted therapeutic strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The review critically analyzes existing literature and research findings concerning the roles of signaling pathways in stem cell behavior regulation, emphasizing their parallels and disparities in cancer cells. It synthesizes information on both direct and indirect modes of cell communication to delineate the complexity of signaling networks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Direct and indirect modes of cell communication intricately regulate the complex signaling pathways governing stem cell behaviors, influencing differentiation potential and tissue regeneration. Alterations in these pathways significantly impact stem cell fate, contributing to disease pathogenesis, including cancer. Understanding these signaling cascades offers insights into developing targeted therapies, particularly cancer treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Understanding the regulation of signaling pathways in stem cells and the specialized subset of cancer stem cells holds promise for innovative therapeutic approaches. By targeting aberrant signaling pathways, tailored interventions may improve treatment outcomes. This review underscores the critical role of signaling pathways in cellular behaviors, offering a pathway toward developing novel, more effective therapies for diverse diseases and disorders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 3","pages":"479-488"},"PeriodicalIF":2.9,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139476365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics 基因多态性和癌症恶病质对接受阿片类镇痛药的患者中纳尔地定药代动力学和肠蠕动的影响。

IF 2.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2024-01-08 DOI: 10.1111/fcp.12976

Emi Nakatsugawa, Takafumi Naito, Kaito Shibata, Ryo Kitajima, Junichi Kawakami

Background/Objectives

Clinical responses to naldemedine vary between individuals with advanced cancer. This is a prospective, single-center, observational study aimed to evaluate the influence of genetic polymorphisms and cachexia status on plasma naldemedine and clinical responses.

Methods

Forty-eight patients being treated with naldemedine for opioid-induced constipation under treatment of cancer pain were enrolled. Plasma naldemedine concentrations were determined on the fourth day or later after administration of naldemedine, and the associations with genotypes, cachexia status, and clinical responses were assessed.

Results

Cancer patients exhibited a large variation in the plasma naldemedine concentrations, and it was correlated with serum total protein level. Patients who were homozygous CYP3A5*3 had a higher plasma concentration of naldemedine than those with the *1 allele. ABCB1 genotypes tested in this study were not associated with plasma naldemedine. A negative correlation was observed between the plasma naldemedine concentration and 4β-hydroxycholesterol level. The plasma naldemedine concentration was lower in patients with refractory cachexia than in those with precachexia and cachexia. While serum levels of interleukin-6 (IL-6) and acute-phase proteins were higher in patients with refractory cachexia, they were not associated with plasma naldemedine. A higher plasma concentration of naldemedine, CYP3A5*3/*3, and an earlier naldemedine administration after starting opioid analgesics were related to improvement of bowel movements.

Conclusion

Plasma naldemedine increased under deficient activity of CYP3A5 in cancer patients. Cachectic patients with a higher serum IL-6 had a lower plasma naldemedine. Plasma naldemedine, related to CYP3A5 genotype, and the initiation timing of naldemedine were associated with improved bowel movements.

背景/目的：晚期癌症患者对纳尔灭定的临床反应因人而异。这是一项前瞻性、单中心、观察性研究，旨在评估基因多态性和恶病质状态对血浆纳尔地定和临床反应的影响：方法：研究纳入了48名正在接受纳尔地定治疗的患者，这些患者在治疗癌痛的过程中因阿片类药物引起便秘。结果：癌症患者的基因型、恶病质状态和临床反应有很大差异：结果：癌症患者血浆中纳尔灭定的浓度变化很大，且与血清总蛋白水平相关。CYP3A5*3等位基因患者的血浆中纳尔灭定浓度高于*1等位基因患者。本研究中检测的 ABCB1 基因型与血浆中纳尔灭定的浓度无关。血浆中纳尔灭定的浓度与 4β- 羟基胆固醇的水平呈负相关。难治性恶病质患者的血浆纳尔德美汀浓度低于先兆性恶病质和恶病质患者。虽然难治性恶病质患者血清中的白细胞介素-6（IL-6）和急性期蛋白水平较高，但它们与血浆中的萘美汀无关。结论：血浆中纳尔灭定、CYP3A5*3/*3的浓度较高，以及在开始使用阿片类镇痛药后较早服用纳尔灭定与肠蠕动的改善有关：结论：在癌症患者CYP3A5活性不足的情况下，血浆中纳尔灭定的含量会增加。血清IL-6较高的癌症患者血浆中纳尔灭定的含量较低。与CYP3A5基因型有关的血浆纳尔地美定和纳尔地美定的开始使用时间与肠蠕动的改善有关。

{"title":"Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics","authors":"Emi Nakatsugawa, Takafumi Naito, Kaito Shibata, Ryo Kitajima, Junichi Kawakami","doi":"10.1111/fcp.12976","DOIUrl":"10.1111/fcp.12976","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Clinical responses to naldemedine vary between individuals with advanced cancer. This is a prospective, single-center, observational study aimed to evaluate the influence of genetic polymorphisms and cachexia status on plasma naldemedine and clinical responses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Forty-eight patients being treated with naldemedine for opioid-induced constipation under treatment of cancer pain were enrolled. Plasma naldemedine concentrations were determined on the fourth day or later after administration of naldemedine, and the associations with genotypes, cachexia status, and clinical responses were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cancer patients exhibited a large variation in the plasma naldemedine concentrations, and it was correlated with serum total protein level. Patients who were homozygous <i>CYP3A5*3</i> had a higher plasma concentration of naldemedine than those with the <i>*1</i> allele. ABCB1 genotypes tested in this study were not associated with plasma naldemedine. A negative correlation was observed between the plasma naldemedine concentration and 4β-hydroxycholesterol level. The plasma naldemedine concentration was lower in patients with refractory cachexia than in those with precachexia and cachexia. While serum levels of interleukin-6 (IL-6) and acute-phase proteins were higher in patients with refractory cachexia, they were not associated with plasma naldemedine. A higher plasma concentration of naldemedine, <i>CYP3A5*3/*3</i>, and an earlier naldemedine administration after starting opioid analgesics were related to improvement of bowel movements.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Plasma naldemedine increased under deficient activity of CYP3A5 in cancer patients. Cachectic patients with a higher serum IL-6 had a lower plasma naldemedine. Plasma naldemedine, related to CYP3A5 genotype, and the initiation timing of naldemedine were associated with improved bowel movements.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 3","pages":"596-605"},"PeriodicalIF":2.9,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/fcp.12976","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats 比较艾塞那肽、恩格列净、槲皮素以及这几种药物的复方制剂对 2 型糖尿病大鼠的抗糖尿病作用。

IF 2.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2023-12-27 DOI: 10.1111/fcp.12975

Yasemin Korkmaz, Burak Dik

Background

Type 2 diabetes, a metabolic disease that involves extended treatment, is rapidly increasing in humans and animals worldwide.

Objectives

This study aimed to compare monotherapy and combined therapy of exenatide, empagliflozin, and quercetin in 67 Wistar Albino male rats.

Methods

The animals were divided into the following seven groups: healthy control, diabetes control, diabetes + sham, diabetes + exenatide (10 μg/kg), diabetes + empagliflozin (50 mg/kg), diabetes + quercetin (50 mg/kg), and diabetes + combination treatment. The treatments were continued for 8 weeks.

Results

At the end of the experiment, glucose and HbA1c levels decreased with all monotherapy treatments and the combination treatments, while insulin levels increased with exenatide and combined treatments. Adiponectin levels increased with empagliflozin, quercetin, and combined treatments, while leptin levels decreased only with combined treatments. All monotherapies caused an increase in total antioxidant levels. Exenatide and quercetin treatments reduced low-density lipoprotein (LDL) levels; therewithal, exenatide and combined treatments increased high-density lipoprotein (HDL) levels. Triglyceride levels decreased in all treatment groups. The homeostatic model assessment for insulin resistance (HOMA-IR) level decreased with the combined treatment; on the contrary, the homeostatic model assessment for β-cell activity (HOMA-β) level increased with empagliflozin, exenatide, and combined treatments.

Conclusion

In conclusion, the antidiabetic effects of exenatide were more pronounced than empagliflozin and quercetin, however, the combined treatment had better antidiabetic and antihyperlipidemic effects than monotherapies. Quercetin could be a supportive or food supplement antidiabetic agent. The exenatide treatment can be recommended for monotherapy in type 2 patients, and the combination of empagliflozin, exenatide, and quercetin may be effective in diabetic patients who need combined therapy.

背景：2型糖尿病是一种需要长期治疗的代谢性疾病，在全球人类和动物中的发病率迅速上升：本研究旨在比较艾塞那肽、恩格列净和槲皮素对67只Wistar Albino雄性大鼠的单药治疗和联合治疗：动物分为以下七组：健康对照组、糖尿病对照组、糖尿病+假治疗组、糖尿病+艾塞那肽（10 μg/kg）组、糖尿病+恩格列净（50 mg/kg）组、糖尿病+槲皮素（50 mg/kg）组、糖尿病+联合治疗组。治疗持续8周：实验结束时，所有单一疗法和联合疗法的血糖和 HbA1c 水平都有所下降，而艾塞那肽和联合疗法的胰岛素水平有所上升。安帕格列净、槲皮素和联合疗法可提高脂联素水平，而只有联合疗法可降低瘦素水平。所有单一疗法都能提高总抗氧化剂水平。艾塞那肽和槲皮素疗法降低了低密度脂蛋白（LDL）水平；与此同时，艾塞那肽和联合疗法提高了高密度脂蛋白（HDL）水平。所有治疗组的甘油三酯水平均有所下降。胰岛素抵抗的稳态模型评估（HOMA-IR）水平随着联合治疗而降低；相反，β细胞活性的稳态模型评估（HOMA-β）水平随着恩格列净、艾塞那肽和联合治疗而升高：总之，艾塞那肽的抗糖尿病效果比恩格列净和槲皮素更明显，但联合治疗的抗糖尿病和降血脂效果比单一疗法更好。槲皮素可作为一种辅助或食物补充抗糖尿病药物。对于 2 型糖尿病患者，可推荐使用艾塞那肽单药治疗，而对于需要联合治疗的糖尿病患者，联合使用恩格列净、艾塞那肽和槲皮素可能会有效。

{"title":"The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats","authors":"Yasemin Korkmaz, Burak Dik","doi":"10.1111/fcp.12975","DOIUrl":"10.1111/fcp.12975","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Type 2 diabetes, a metabolic disease that involves extended treatment, is rapidly increasing in humans and animals worldwide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to compare monotherapy and combined therapy of exenatide, empagliflozin, and quercetin in 67 Wistar Albino male rats.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The animals were divided into the following seven groups: healthy control, diabetes control, diabetes + sham, diabetes + exenatide (10 μg/kg), diabetes + empagliflozin (50 mg/kg), diabetes + quercetin (50 mg/kg), and diabetes + combination treatment. The treatments were continued for 8 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At the end of the experiment, glucose and HbA1c levels decreased with all monotherapy treatments and the combination treatments, while insulin levels increased with exenatide and combined treatments. Adiponectin levels increased with empagliflozin, quercetin, and combined treatments, while leptin levels decreased only with combined treatments. All monotherapies caused an increase in total antioxidant levels. Exenatide and quercetin treatments reduced low-density lipoprotein (LDL) levels; therewithal, exenatide and combined treatments increased high-density lipoprotein (HDL) levels. Triglyceride levels decreased in all treatment groups. The homeostatic model assessment for insulin resistance (HOMA-IR) level decreased with the combined treatment; on the contrary, the homeostatic model assessment for β-cell activity (HOMA-β) level increased with empagliflozin, exenatide, and combined treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, the antidiabetic effects of exenatide were more pronounced than empagliflozin and quercetin, however, the combined treatment had better antidiabetic and antihyperlipidemic effects than monotherapies. Quercetin could be a supportive or food supplement antidiabetic agent. The exenatide treatment can be recommended for monotherapy in type 2 patients, and the combination of empagliflozin, exenatide, and quercetin may be effective in diabetic patients who need combined therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 3","pages":"511-522"},"PeriodicalIF":2.9,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antimalarial activities of benzothiazole analogs: A systematic review 苯并噻唑类似物的抗疟活性：系统综述。

IF 2.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology

Pub Date : 2023-12-26 DOI: 10.1111/fcp.12974

Linh Tran, Vo Linh Tu, Mohammad Najm Dadam, Jeza Muhamad Abdul Aziz, Tran Le Dinh Duy, Hajer Hatim Hassan Ahmed, Patrick Amanning Kwaah, Hoang Nghia Quoc, Truong Van Dat, Satoshi Mizuta, Kenji Hirayama, Nguyen Tien Huy

Background

Benzothiazole derivatives have been reported to possess a wide range of biological activities, including antimalarial activity. This systematic review aims to summarize and evaluate the antimalarial activities of benzothiazole analogs.

Methods

We conducted an electronic search using nine databases in October 2017 and subsequently updated in September 2022. We included all original in vitro and in vivo studies that documented the antimalarial activities of compounds containing benzothiazole analogs with no restriction. The risk of bias of each included study was assessed by ToxRTool.

Results

Twenty-eight articles were included in our study, which are in vitro, in vivo, or both. Of these, 232 substances were identified to have potent antiplasmodial activity against various strains of the malaria parasite. Benzothiazole analogs show different antimalarial mechanisms, including inhibition of Plasmodium falciparum enzymes in in vitro studies and inhibition of blood parasites in in vivo studies.

Conclusions

Benzothiazole derivatives are promising substances for treating malaria. The structure–activity relationship studies suggest that the substitution pattern of the benzothiazole scaffold plays a crucial role in determining the antimalarial activity of the analog.

背景：据报道，苯并噻唑衍生物具有广泛的生物活性，包括抗疟活性。本系统综述旨在总结和评估苯并噻唑类似物的抗疟活性：我们于 2017 年 10 月使用九个数据库进行了电子检索，随后于 2022 年 9 月进行了更新。我们不受限制地纳入了所有记录了含有苯并噻唑类似物的化合物抗疟活性的体外和体内原始研究。我们使用 ToxRTool 对每项纳入研究的偏倚风险进行了评估：我们的研究共纳入了 28 篇文章，这些文章或为体外研究，或为体内研究，或两者兼而有之。其中有 232 种物质被鉴定出对各种疟原虫菌株具有强效抗疟活性。苯并噻唑类似物显示出不同的抗疟机制，包括在体外研究中抑制恶性疟原虫酶，在体内研究中抑制血液中的寄生虫：结论：苯并噻唑衍生物是治疗疟疾的有效物质。结构-活性关系研究表明，苯并噻唑支架的取代模式在决定类似物的抗疟活性方面起着至关重要的作用。

{"title":"Antimalarial activities of benzothiazole analogs: A systematic review","authors":"Linh Tran, Vo Linh Tu, Mohammad Najm Dadam, Jeza Muhamad Abdul Aziz, Tran Le Dinh Duy, Hajer Hatim Hassan Ahmed, Patrick Amanning Kwaah, Hoang Nghia Quoc, Truong Van Dat, Satoshi Mizuta, Kenji Hirayama, Nguyen Tien Huy","doi":"10.1111/fcp.12974","DOIUrl":"10.1111/fcp.12974","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Benzothiazole derivatives have been reported to possess a wide range of biological activities, including antimalarial activity. This systematic review aims to summarize and evaluate the antimalarial activities of benzothiazole analogs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted an electronic search using nine databases in October 2017 and subsequently updated in September 2022. We included all original in vitro and in vivo studies that documented the antimalarial activities of compounds containing benzothiazole analogs with no restriction. The risk of bias of each included study was assessed by ToxRTool.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-eight articles were included in our study, which are in vitro, in vivo, or both. Of these, 232 substances were identified to have potent antiplasmodial activity against various strains of the malaria parasite. Benzothiazole analogs show different antimalarial mechanisms, including inhibition of <i>Plasmodium falciparum</i> enzymes in in vitro studies and inhibition of blood parasites in in vivo studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Benzothiazole derivatives are promising substances for treating malaria. The structure–activity relationship studies suggest that the substitution pattern of the benzothiazole scaffold plays a crucial role in determining the antimalarial activity of the analog.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"38 3","pages":"410-464"},"PeriodicalIF":2.9,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139037578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0